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Abstract 
 
Background: Despite successful restoration of epicardial vessel patency with primary 
percutaneous coronary intervention (pPCI), coronary microvascular injury (MVI) occurs in a 
large proportion of STEMI patients, adversely affecting clinical and functional outcome. 
Ticagrelor has been reported to increase plasma adenosine levels, which might have a protective 
effect on the microcirculation. We investigated if ticagrelor maintenance therapy after 
revascularized STEMI is associated with less MVI compared to prasugrel maintenance therapy. 
Methods: A total of 110 STEMI patients received a loading dose of ticagrelor and were 
randomized to maintenance therapy of ticagrelor (n=56) or prasugrel (n=54) after pPCI. The 
primary outcome was MVI at 1 month, as determined with the index of microcirculatory 
resistance (IMR) in the infarct-related artery. Cardiovascular magnetic resonance imaging was 
performed during the acute phase and at one month. 
Results: The primary outcome of IMR was not superior in ticagrelor or prasugrel treated patients 
(ticagrelor 21 [15-39] U, prasugrel 18 [11-29] U, p=0.08). Recovery of microcirculatory 
resistance over time was not better in patients with ticagrelor versus prasugrel (ticagrelor -13.9 U 
vs. prasugrel -13.5 U, p=0.54). Intramyocardial hemorrhage was observed less frequently in 
patients with ticagrelor (23% vs. 43%, p=0.04). At one month no difference in infarct size was 
observed (ticagrelor 7.6 [IQR 3.7-14.4] g, prasugrel 9.9 [IQR 5.7-16.6] g, p=0.17). The 
occurrence of microvascular obstruction was not different in patients on ticagrelor (28%) or 
prasugrel (41%, p=0.35). Plasma adenosine concentrations were not different during the index 
procedure and during maintenance therapy with ticagrelor or prasugrel. 
Conclusions: In patients with STEMI, ticagrelor maintenance therapy was not superior to 
prasugrel in preventing MVI in the infarct-related territory as assessed by IMR and this resulted 
in a comparable infarct size at one month. 
Clinical Trial Registration: URL: https://clinicaltrials.gov Unique identifier: NCT02422888 
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Clinical Perspective 
 
What is new? 
• This first randomized trial comparing maintenance treatment with ticagrelor or prasugrel 
after primary PCI showed no differential effect on the extent of microvascular injury and 
infarct size at one month after primary PCI. 
• The attributed pleotropic benefits of ticagrelor through the adenosine metabolism could 
not be confirmed in a STEMI population and plasma adenosine levels were actually not 
increased in patients treated with ticagrelor. 
 
What are the clinical implications? 
• International guidelines provide a similar recommendation level for ticagrelor and 
prasugrel but randomized trials comparing the two head-to-head are lacking. 
• Microvascular injury and infarct size are both predictors for long-term clinical outcome 
after primary PCI and are considered as important treatment targets. 
• No difference was observed for ticagrelor versus prasugrel maintenance therapy 
regarding microvascular injury or infarct size after PCI-treated STEMI. 
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Introduction 
The recommended treatment of ST-elevation myocardial infarction (STEMI) by clinical 
guidelines includes prompt mechanical reperfusion with primary percutaneous intervention 
(pPCI) and concomitant antithrombotic therapy with a P2Y12 inhibitor plus aspirin
1. Based on 
two landmark trials, ticagrelor and prasugrel are recommended over clopidogrel because of 
stronger and more rapid platelet inhibition and superior efficacy2, 3. Comparisons between 
ticagrelor and prasugrel are scarce and primarily based on observational data4, 5, with the 
exception of the Prague-18 randomized trial that compared the efficacy and safety of both 
thienopyridines in patients undergoing pPCI for acute MI, and failed to show any differences in 
patient outcomes at short-term6. Of note, these studies have focused on the antithrombotic 
potency of both drugs, and not on other (off-target) specific pharmacological effects that might 
have a salutary effect on reperfused myocardium. One of such off-target properties is the unique 
ability of ticagrelor to block the equilibrative nucleoside transporter (ENT) -1 receptor, 
increasing local extracellular adenosine levels, particularly at sites of  increased adenosine 
formation such as ischemia and tissue injury7. Adenosine is a microcirculatory vasodilator and 
thus ticagrelor mediated increased plasmatic adenosine levels might reduce coronary 
microvascular injury (MVI) caused by reperfusion damage in revascularized STEMI, which was 
previously documented in experimental studies8. It was demonstrated that adenosine-induced 
coronary blood flow could be enhanced by ticagrelor9 and resulted in improved peripheral 
microvascular function, which could not be observed with prasugrel or clopidogrel10. The high 
incidence of MVI and the associated important prognostic implications makes this condition a 
key treatment target in STEMI11, 12. MVI may be quantified with either the index of 
microcirculatory resistance (IMR), a thermodilution derived intracoronary physiology index, or 
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with late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR), which is 
strongly associated with mortality in revascularized STEMI13. 
 We have conducted a randomized clinical trial to determine whether after an initial 
loading dose with ticagrelor, ticagrelor maintenance therapy following pPCI in STEMI reduces 
MVI, compared to maintenance therapy with prasugrel. The study also aimed to establish the 
effect of ticagrelor and prasugrel therapy on microvascular obstruction (MVO), intramyocardial 
haemorrhage (IMH) and infarct size as determined with CMR. 
 
Methods 
Study design, participant selection and outcome measurements 
The REDUCE-MVI trial [NCT02422888] is a multicenter superiority trial with a Prospective 
Randomized Open Blinded Endpoint (PROBE) design. The study complies with the Declaration 
of Helsinki and the study was approved by the institutional review board (local medical ethics 
committee). Upon request, the analytic methods will be made available to other researchers for 
purposes of reproducing the results or replicating the procedure, the data and study materials will 
not be made available. The trial was conducted in 6 centres in the Netherlands and Spain and the 
study design has been published previously14. In brief, patients were eligible for study 
participation when they presented with STEMI1 <12 hours after onset of symptoms, received a 
loading dose of ticagrelor (180mg), underwent successful pPCI of the infarct-related artery with 
a drug eluting stent and had a concomitant intermediate lesion in the non-infarct related 
vessel(s). This inclusion criteria was introduced to avoid repeat invasive procedures solely for 
study purposes. When all in- and exclusion criteria were fulfilled (Supplemental Methods 1) and 
witnessed oral informed consent was obtained, patients were subjected to intracoronary 
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physiology measurements during the index procedure. After the index procedure patients were 
asked to confirm study participation by written informed consent. Subsequently, patients were 
randomized to ticagrelor or prasugrel maintenance therapy (permuted block randomization with 
randomly selected block sizes, stratified according to study centre). All patients received a 
loading dose of ticagrelor pre PPCI. Patients randomized to ticagrelor continued with ticagrelor 
90 mg BID whereas patients randomized to prasugrel received a loading dose of 60 mg and then 
continued with prasugrel 10 mg SID to mitigate increased platelet reactivity after switching from 
ticagrelor to prasugrel as earlier reported15. 
 The primary aim was to determine if ticagrelor maintenance therapy as compared to 
prasugrel maintenance therapy is associated with less MVI as assessed by IMR in the infarct-
related artery at one month follow-up. IMR assessment was performed simultaneously with FFR 
measurement at one month follow-up. CMR derived MVO and IMH at the acute phase and 
infarct size and LVEF at 1 month were considered as secondary outcome measures. As a safety 
objective, we compared the occurrence of bleeding complications between patients on ticagrelor 
or prasugrel maintenance therapy during one month follow-up, classified by the BARC criteria16. 
Major adverse clinical events were prospectively collected between the index event and one 
month follow-up and included death, myocardial infarction, stent thrombosis and coronary 
revascularization17, 18. 
Intracoronary hemodynamic physiology indices 
Coronary flow reserve (CFR), IMR, baseline microcirculatory resistance (BMR) and FFR were 
measured with a coronary pressure/temperature wire (Certus, Abbott, Minnesota, USA). All 
measurements were extracted from the RadiAnalyzer™ Xpress, QUANTIEN™ console and all 
traces were analyzed offline by an independent blinded expert locally with RadiView™ Software 
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(Abbott, St. Paul, Minnesota, USA). A second independent operator in our hospital checked all 
analyzed traces and if there was a discordance, both operators discussed the discordance and 
adjusted the values as appropriate. BMR in our study was calculated by multiplying the resting 
distal pressure by the mean resting transit time19. 
CMR imaging 
Cardiovascular magnetic resonance (CMR) imaging was performed between 2 to 7 days and 1 
month after pPCI using a 1.5-T clinical scanner (Siemens Healthcare, Erlangen, Germany). 
Scanning protocol included cine imaging, T2-weighted imaging and LGE. Left ventricular (LV) 
volumes and function were calculated from the short-axis cine images. T2-weighted images were 
used to identify IMH. LGE images were used for calculation of infarct size and identification of 
MVO. Infarct size is expressed in grams, as well as % of LV mass. A detailed description on 
acquisition techniques, CMR parameters and post-processing is provided in Supplemental 
Methods 2. 
Ticagrelor, adenosine and P2Y12-inhibition levels 
At the index event, at day 3 and at one month follow-up, blood samples were collected for 
measurement of levels of ticagrelor, its active metabolite AR-C124910XX and adenosine plasma 
concentrations (APC). The samples were sent to specialized laboratories blinded for analysis 
(Bioanalytical Covance Laboratory, Indianapolis, United States and Q&Q labs AB, Gothenburg, 
Sweden, respectively (measurement details in supplement). Furthermore, platelet aggregation 
was quantified from the same blood samples (VerifyNow System, Accumetrics, San Diego, CA, 
USA). High platelet reactivity (HPR) was defined as P2Y12 reaction units (PRU) > 235
20 and 
low platelet reactivity (LPR) was present when PRU < 8521. A detailed description is provided in 
Supplemental Methods 3. 
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Sample size calculation and statistical analyses 
The sample size calculation is based on a superiority design with the null hypothesis that IMR at 
30 days is equal in patients with ticagrelor- compared to prasugrel maintenance therapy. A 
between-group difference in mean IMR of 7 in favor of ticagrelor was considered clinically 
relevant. We required 47 subjects in each treatment group to detect this difference with a power 
of 80% (two-sided testing at α=0.05) assuming a standard deviation of 12 in both groups. We 
increased the sample size by 15% to account for patients being lost to follow-up, which resulted 
in a total sample size of 110 patients. A blinded interim analysis at 50% of inclusion was planned 
and the results including the decision of the data safety monitoring board are described in the 
Supplemental Methods 4. Our study was not powered for specific differences in secondary 
endpoints. To assess a difference in dichotomous and/or categorical variables Chi-square test or 
Fisher’s exact test was used. To assess the difference in continuous variables between both 
treatment groups, we used the independent samples t-test for normally distributed variables and 
the Mann-Whitney U test in case the variable was not normally distributed. To investigate the 
association between continuous variables we used Pearson’s correlation for pairs of normally 
distributed variables and Spearman’s correlation in case of skewness or extreme outliers on 
variables. We considered a p-value of <0.05 as statistically significant. 
 
Results 
Study population characteristics 
In total 56 patients were randomized to ticagrelor 90 mg BID and 54 patients to prasugrel 10 mg 
SID (Figure 1). We have provided a screenings log during the inclusion period with 
accompanying in- and exclusion criteria in the supplemental Figure 1. During the complete 
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follow-up period, the allocated therapy was received by 51 patients in the ticagrelor group and 53 
patients in the prasugrel group. A switch to triple therapy with clopidogrel occurred in 4 patients 
randomized to ticagrelor and in 1 patient randomized to prasugrel because of either new onset 
atrial fibrillation (clopidogrel and new oral anticoagulants (NOAC)) or left ventricular thrombus 
(clopidogrel and acenocoumarol). In the ticagrelor group, 1 patient switched to prasugrel because 
of dyspnea associated with ticagrelor. Lost to follow-up was equally present in both groups (n=3 
vs. n=3) and IMR could not be obtained or analyzed in 2 patients in the ticagrelor group and 3 
patients in the prasugrel group. Primary endpoint analysis could thus be performed in 99 patients 
(ticagrelor n=51, prasugrel n=48). Clinical and procedural characteristics were well balanced 
between the two treatment groups (Table 1 and Table 2). IMR and blood sampling during the 
index procedure was performed at 96±36 minutes after ticagrelor loading. 
IMR, BMR and CFR measurements 
IMR during the index procedure was not lower in the ticagrelor- compared to the prasugrel group 
(Figure 2). After a mean follow-up of 31±7 days, the primary endpoint of IMR was not superior 
in the ticagrelor group (ticagrelor 21 [15-39] U, prasugrel 18 [11-29] U, p=0.08). Improvement 
of microvascular function over time was also non-superior between both groups (IMR ticagrelor 
-13.9 U vs. prasugrel -13.5 U, p=0.54). CFR, improvement of CFR over time and BMR were 
also not statistically different, as represented in Table 3. 
Infarct size and CMR 
Infarct size, as represented by creatine kinase (CK), creatine kinase-MB (CK-MB) and troponin 
T peak levels, were not different between treatment groups (Table 1). Baseline CMR was 
performed in 81 patients and follow-up CMR was performed in 96 patients. At baseline, the 
occurrence of MVO was not statistically different in patients on ticagrelor (28%) or prasugrel 
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(41%, p=0.35), but IMH was more frequently present in patients with prasugrel (ticagrelor 23% 
vs. prasugrel 43%, p=0.04). Total infarct size (ticagrelor 7.6 g vs. prasugrel 9.9 g, p=0.17) and 
LVEF (ticagrelor 53% vs. prasugrel 52%, p=0.61) was not superior in the ticagrelor- versus 
prasugrel group (Table 4). 
Adenosine and Ticagrelor levels 
APC was available for 106 patients at baseline, 77 patients at day 3 and 105 patients at one 
month follow-up. At baseline and at one month follow-up, APC were similar in patients 
randomized to ticagrelor or prasugrel, as represented in Figure 3. At day 3, similar levels of APC 
were found in the two groups; ticagrelor (47.1 (IQR 20.5-112.6) nM vs. prasugrel (75.4 (IQR 
27.2-222.8) nM, p=0.22). The median APC at 1 month was 56.7 (IQR 28.4-298.7) nM for 
ticagrelor and 92.8 (IQR 23.8-422.7) nM for prasugrel (p=0.56). At the acute moment, there was 
no significant correlation between APC and IMR or CFR. There was a significant correlation 
between APC and CFR but not with IMR at 30 days (Supplemental Table 1). The levels of 
ticagrelor and active metabolite AR-C124910XX were obtained in 110 patients at baseline and 
102 patients at one month follow-up. Ticagrelor levels are represented in a scatter plot for 
patients randomized to ticagrelor and prasugrel with specification of those patients who switched 
to a different therapy during follow-up (Figure 4). There was no significant difference in AR-
C124910XX levels between the two groups during the index procedure (155.0 (IQR 0.0-356.0) 
ng/mL for ticagrelor vs. 50.5 (IQR 0.0-298.8) ng/mL for prasugrel, p=0.32). At 1 month, AR-
C124910XX levels in the ticagrelor group were 182.5 (IQR 124.3-333.0) ng/mL vs. 0.0 (0-0) 
ng/mL in the prasugrel group, p<0001. There was no correlation between ticagrelor levels and 
IMR or CFR values (Supplemental Table 1). 
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Platelet inhibition 
At baseline, platelet inhibition testing was performed in 94 (85%) patients and was not superior 
in one of both treatment groups (Table 5). After 1 month of maintenance therapy, no difference 
in platelet inhibition, HPR and LPR was observed between the two treatment groups. 
Clinical outcome 
From randomization to follow-up, bleeding complications were more frequent in the prasugrel 
group as compared to the ticagrelor group (29% vs. 11%, p=0.02), primarily due to a higher 
number of BARC 1 bleeding complications in the prasugrel group (Supplemental Table 2). 
BARC ≥2 bleeding complications occurred in two patients (3.7%) randomized to ticagrelor and 
were not observed in the prasugrel group. There was no significant difference in ticagrelor levels 
in patients with or without the occurrence of bleeding at one month follow-up (Supplemental 
Table 2). However, in patients with elevated ticagrelor levels at one month follow-up (based on 
Q3: cut-off value of >811 ng/mL) there were significant more often bleedings at one month 
follow-up (33.3% (4 of 12) versus 5.3% (2 of 38), p=0.024). In total 3 patients died of non-
cardiac causes (respiratory insufficiency due to chronic obstructive pulmonary disease (n=1), 
respiratory insufficiency due to interstitial pneumonitis caused by metastatic breast cancer (n=1) 
and complicated endoscopic retrograde cholangio- and pancreaticography with septic shock 
(n=1). Myocardial infarction, stent thrombosis or repeat revascularization did not occur in any of 
the patients during the study period. 
 
Discussion 
This is the first randomized trial that compared maintenance therapy of ticagrelor with 
maintenance therapy of prasugrel on coronary microvascular injury (MVI) after successful pPCI 
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in STEMI. Our main findings are: 1. MVI as assessed by IMR was not reduced with ticagrelor 2. 
At 1 month, no differences were observed regarding infarct size and LV function between the 
two treatment groups. 3. Plasma adenosine levels were not increased with ticagrelor during 
maintenance therapy. 4. In patients randomized to prasugrel, minor bleedings and IMH were 
slightly more frequently observed. 
 MVI is considered as an important treatment target in mechanically reperfused STEMI 
because of the high incidence and significant prognostic implications of this condition22. There 
are 3 phases following PPCI in which MVI could be attenuated to limit infarct size. The first 
phase directly following primary PCI consists of endothelial activation and/or injury, 
inflammatory cell plugging, microvascular destruction resulting in intramyocardial hemorrhage12 
and formation of microthrombi causing microvascular obstruction (no-reflow). The second phase 
(hours-days) is dictated by infiltrating cells. The third phase (days-months) is characterized by 
irreversible damage of the microcirculation. Increased levels of adenosine potentially act on all 
these mechanisms8. MVI may be assessed with non-invasive methods, such as CMR and 
positron emission tomography or invasively using hyperemic microcirculatory resistance and 
IMR23. A major advantage of invasive MVI assessment with IMR is that it allows for risk 
stratification and evaluation of adjunctive treatment strategies during the acute phase of STEMI. 
The normal value of IMR in non-infarct related arteries is considered to be < 25 24, 25. IMR in 
infarct-related arteries has been reported to be 31 (IQR 21-49) after primary PCI13. Strongly 
increased IMR values >40 in STEMI are associated with the extent of MVO, IMH, myocardial 
salvage and mortality 13, 26, 27 and recovery of microcirculatory resistance has been described as a 
strong predictor of functional outcome after pPCI28. In the present study, we did not observe 
superiority of ticagrelor in reduction of IMR at 1 month or IMR recovery at follow-up as 
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compared to prasugrel treated patients. To avoid override of endogenous adenosine by the 
intracoronary infused adenosine during IMR measurement we also included resting 
microcirculatory resistance (BMR). However, no difference in BMR between groups was 
observed. It should be noted though that the distribution of observed values was very large, 
limiting the value of this index. In our study, all patients received a loading dose of ticagrelor, 
which might have influenced the development of MVI. However, MVI was still present in 46% 
of our population, which is similar to studies with prasugrel loading dose23. 
 We did observe a slightly lower incidence of CMR-derived IMH in ticagrelor treated 
patients, reflecting MVI with extravasation of erythrocytes during the acute phase. IMH is 
closely related to MVO12 and predicts both functional and clinical outcome after STEMI. 
Recently, it was shown that IMH is even more closely associated with adverse outcome than 
MVO29. We did not find a significant between-group difference in CMR-derived MVO, and our 
study was not powered for these secondary outcomes. 
 Previous studies, that led to the design of the present trial, reported on the potential 
beneficial effects of ticagrelor on MVI that were attributed to increased plasma levels of 
adenosine8. These experimental studies in animals30-32 were corroborated in healthy volunteers 
and ACS patients7,9, 33,10 showing enhanced coronary blood flow and improvement of peripheral 
and coronary microvascular function34. In contrast, the absence of a differential effect on micro- 
and macrovascular function and the inability to improve myocardial reperfusion with ticagrelor 
has also been reported 35-37. In the present study we could not detect a difference in adenosine 
plasma concentrations during ticagrelor or prasugrel maintenance therapy. However, it should be 
noted that the measurement of endogenous plasma concentration in daily clinical practice is very 
cumbersome due to the extreme short half-life of adenosine and rapid cellular uptake after blood 
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sampling, despite the application of adequate stop solution and dedicated syringes, leading to a 
wide range in measured APC38. Also, due to active endothelial adenosine metabolism, 
circulating adenosine does not represent myocardial interstitial adenosine concentration, and we 
were not able to measure local adenosine levels at tissue level. The ongoing ISAR-REACT-5 
trial (NCT01944800) currently investigates the long-term clinical outcome in ACS patients with 
either ticagrelor versus prasugrel maintenance therapy39. A substudy of this trial investigated the 
potential effect of reticulated platelets (RPs) on ADP mediated platelet aggregation in 124 
patients with ACS treated with ticagrelor or prasugrel. They reported that RPs (increased during 
ACS) are less inhibited by prasugrel compared to ticagrelor, resulting in increased platelet 
reactivity in the prasugrel group40. However, in our study, platelet reactivity was equal in 
patients with prasugrel and ticagrelor. There was a significant correlation between ticagrelor 
levels and platelet inhibition at the acute moment, but not at one-month follow-up. This might be 
due to the fact that at follow-up a per-protocol analysis was performed in a smaller group of 
patients (n=53) as compared to at the acute moment. 
 Finally, we observed a slightly larger proportion of BARC 1 minor bleedings in patients 
on prasugrel, which is probably not of clinical importance41, 42. In patients with ticagrelor 
maintenance therapy, elevated ticagrelor levels were associated with a mild increase in bleeding 
at one month follow-up. Importantly, the current study was not designed or powered to detect 
differences in clinical outcome. The randomized Prague-18 trial6, as well as a meta-analysis did 
not show a difference in clinical outcome and major bleedings complications between ticagrelor 
and prasugrel4. Future randomized trials with sufficient power will establish the difference in 
long-term clinical outcome between prasugrel and ticagrelor maintenance therapy in STEMI. 
 
D
ow
nloaded from
 http://ahajournals.org by on January 17, 2019
10.1161/CIRCULATIONAHA.118.035931 
15 
Limitations 
Before pPCI all patients were loaded with ticagrelor because this is standard care in the 
participating centers, which might have modified microvascular injury at the index event. The 
sample size calculation was based on a study among patients with stable CAD43, because at the 
time of protocol drafting no data were available with IMR values 1 month post PPCI in STEMI. 
It should be underlined that the observed standard deviation is larger than what we initially 
expected (SD 12), leading to a decreased power. With the increased variability, 128 additional 
patients would need to be included to achieve a power of 80%. However, given that the observed 
effect was in the opposite direction than hypothesized, it is unlikely that adding 99 extra patients 
to our study would yield a significant improvement of IMR in the ticagrelor group. The relatively 
low rates of classic risk factors, small infarct size and preserved EF could have influenced IMR 
values as well as the potential effects of the pharmacological intervention. We have used late 
gadolinium enhancement to detect MVO, which is less sensitive compared to first pass perfusion 
imaging or early gadolinium enhancement, however has the highest prognostic value44. The 
administration of adenosine intravenously during IMR measurements could theoretically 
influence MVI. However the values as observed in our cohort are comparable to other STEMI-
cohorts as recently published45. Also, the natural recovery of microvascular dysfunction over 
time might have diluted the positive effects of ticagrelor, despite the fact that microcirculatory 
resistance is still hampered in 50% of patients at 1 month46. Finally, we included just a fraction 
of all screened STEMI patients due to the rather complex study design of our proof-of-principle 
study and thus it is not possible to extrapolate our results to all STEMI patients. 
Conclusions 
In patients with STEMI, ticagrelor maintenance therapy was not superior to prasugrel in 
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preventing microvascular injury as assessed with IMR at 1 month follow-up and this resulted in a 
comparable infarct size at one month. 
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Table 1. Baseline characteristics 
 
 
Ticagrelor (n=56) 
Median [IQR], 
Mean±SD, n [n%] 
Prasugrel (n=54) 
Median [IQR], 
Mean±SD, n [n%] 
p-value 
 
Age [years] 60.2±10.1 61.0±8.8 0.69 
Sex [male] 49 [87.5] 45 [83.3] 0.54 
BMI [kg/m2] 27.2±3.8 27.8±3.7 0.42 
Symptom-balloon time [minutes] 191 [126-340] 146 [98-322] 0.10 
Loading dose ticagrelor 56 [100.0] 54 [100.0] 1.00 
Loading dose-balloon time [minutes] 79±40 77±48 0.18 
Loading dose-IMR time [minutes] 114±39 103±30 0.24 
Medical history    
Hypertension 20 [35.7] 13 [24.1] 0.18 
Diabetes mellitus 7 [12.5] 4 [7.4] 0.37 
Smoking 26 [46.4] 21 [38.9] 0.47 
Hypercholesterolemia 12 [21.4] 11 [20.4] 0.89 
Family history of CAD 19 [33.9] 23 [42.6] 0.35 
Previous PCI 3 [5.4] 1 [1.9] 0.33 
Medication before PPCI    
ASA 6 [10.7] 3 [5.6] 0.30 
Lipid lowering medication 12 [21.4] 9 [16.7] 0.53 
ACE-i or ARB 12 [21.4] 9 [16.7] 0.53 
Beta-blocker 8 [14.3] 4 [7.4] 0.25 
CCB 4 [7.1] 5 [9.3] 0.68 
Laboratory peak values    
CK [U/L] 1040 [441-1913] 1127 [453-2171] 0.86 
CK-MB [µg/L] 86 [28-207] 102 [37-216] 0.73 
Troponin T [µg/L] 1.82 [0.58-5.04] 1.73 [0.38-4.14] 0.39 
ACE-i: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker, ASA: 
acetylsalicylic acid, BMI: body mass index, CAD: coronary artery disease, CCB: calcium channel 
blocker, CK: Creatine kinase, CK-MB: Creatine kinase-MB, IMR: index of microcirculatory resistance, 
SD: standard deviation, PCI: percutaneous coronary intervention. 
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Table 2. Coronary angiography and PCI parameters at the index procedure 
 
 
Ticagrelor (n=56) 
Mean±SD,  
Median [IQR], n [n%] 
Prasugrel (n=54) 
Mean±SD,  
Median [IQR], n [n%] 
p-value 
 
2-vessel disease 42 [75.0] 41 [75.9] 0.91 
3-vessel disease 14 [25.0] 13 [24.1] 0.91 
Cardiogenic shock 0 [0] 0 [0] 1.00 
Radial access 53 [94.6] 52 [96.3] 0.43 
Angiographic characteristics culprit    
LAD 17 [30.4] 19 [35.2] 0.59 
LCX 15 [26.8] 13 [24.1] 0.74 
RCA 24 [42.9] 22 [40.1] 0.82 
TIMI-flow pre pPCI 0 31 [55.4] 31 [57.4] 0.96 
1 6 [10.7] 3 [5.6]  
2 13 [23.2] 13 [24.1]  
3 6 [10.7] 7 [13.0]  
TIMI-flow post pPCI   0 0 [0] 0 [0] 0.34 
1 2 [3.6] 4 [7.4]  
2 11 [19.6] 4 [7.4]  
3 43 [76.8] 46 [85.2]  
TFC 41.5 [30.5-65.3] 39.0 [29.0-54.5] 0.58 
cTFC 37.5 [24.3-56.0] 34.0 [21.8-50.5] 0.40 
MBG  0 1 [1.8] 0 [0] 0.98 
1 7 [12.5] 7 [13.0]  
2 7 [12.5] 8 [14.8]  
3 41 [73.2] 39 [72.2]  
PCI characteristics culprit    
Stent length [mm] 34.07±15.03 32.07±15.6 0.50 
Stent diameter [mm] 3.56±0.57 3.66±0.50 0.35 
Thrombectomy 4 [7.1] 7 [13.0] 0.31 
Pre-dilatation 33 [58.9] 29 [53.7] 0.58 
Post-dilatation 18 [32.1] 13 [24.1] 0.35 
Glycoprotein IIb/IIIa inhibitor 7 [12.5] 6 [11.1] 0.92 
cTFC: corrected TIMI frame count, LAD: left anterior descending artery, LCX: left circumflex artery, 
MBG: myocardial blush grade, PCI: percutaneous coronary intervention, pPCI: primary percutaneous 
intervention, RCA: right coronary artery, SD: standard deviation, TIMI: thrombolysis in myocardial 
infarction, TFC: TIMI frame count. 
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Table 3. Intracoronary hemodynamic measurements at baseline and one month follow-up 
 
Parameter 
 
Time 
 
Ticagrelor 
Mean±SD, Median [IQR] 
Prasugrel 
Mean±SD, Median [IQR] 
p-value 
 
IMR (U) Baseline 33 [16-48] 25 [15-50] 0.74 
 Follow-up 21 [15-39] 18 [11-29] 0.08 
 Δ -13.9±39.2 -13.5±31.1 0.96 
BMR (U) Baseline 68.4 [46.0-96.6] 62.5 [34.4-119.3] 0.76 
 Follow-up 95.7 [58.5-144.8] 80.9 [50.5-121.4] 0.24 
 Δ -14.5±57.9 -14.5±69.3 1.00 
CFR Baseline 2.18±1.24 2.13±1.12 0.84 
 Follow-up 3.70±1.76 3.86±1.76 0.66 
 Δ 1.59±1.83 1.75±1.89 0.68 
FFR Baseline 0.94±0.06 0.94±0.06 0.70 
 Follow-up 0.93±0.06 0.91±0.08 0.19 
 Δ -0.01±0.07 -0.02±0.05 0.23 
CFR: coronary flow reserve, FFR: fractional flow reserve, IMR: index of microcirculatory resistance, 
IQR: interquartile range, SD: standard deviation, ∆: delta. 
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Table 4. Infarct size as defined by laboratory values and CMR characteristics 
 
 
Ticagrelor 
Median [IQR], 
Mean±SD, n [n%] 
Prasugrel 
Median [IQR],  
Mean±SD, n [n%] 
p-value 
 
Baseline CMR 40 CMRs* (70%) 42 CMRs* (78%)  
MVO present [yes] 11 [27.5%] 17 [40.5%] 0.35 
IMH present [yes] 8 [22.9%] 18 [42.9%] 0.04 
Edema [g] 26.2±20.1 33.2±18.2 0.12 
Infarct size [g] 10.5 [5.1-22.6] 13.6 [7.2-23.7] 0.29 
MSI [%] 69.8±27.8 73.6±19.4 0.50 
1 month follow-up CMR 49 CMRs (89%) 47 CMRs (90%)  
LVEDV [ml] 179.9±37.4 183.7±39.8 0.63 
LVEDV [ml/m2] 87.9±16.7 88.7±18.0 0.82 
LVESV [ml] 85.2±28.0 89.7±33.6 0.48 
LVESV [ml/m2] 41.6±13.5 43.5±16.9 0.54 
LVEF [%] 53.3±8.1 52.5±8.3 0.61 
LVED mass [g/m2] 52.9±11.4 52.7±9.0 0.92 
Infarct size [g] 7.6 [3.7-14.4] 9.9 [5.7-16.6] 0.17 
Infarct size [% of LV] 7.6 [3.4-12.5] 8.7 [5.4-13.7] 0.14 
CMR: cardiac magnetic resonance imaging, IMH: intramyocardial haemorrhage, IQR: interquartile range, 
LV: left ventricular, LVEDV: left ventricular end-diastolic volume, LVEDVi: indexed left ventricular 
end-diastolic volume, LVEF: left ventricular ejection fraction, LVESV: left ventricular end-systolic 
volume, LVESVi: indexed left ventricular end-systolic volume, MSI: myocardial salvage index, MVI: 
microvascular injury, SD: standard deviation. *Not all of the baseline CMR’s were eligible to assess 
MVO and IMH. There were 82 CMR’s in which MVO (40 in ticagrelor group and 42 in prasugrel group) 
and 77 CMR’s in which IMH (35 in ticagrelor group and 42 in prasugrel group) could be assessed. 
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Table 5. P2Y12 platelet inhibition 
 
Parameter 
 
Time 
 
Ticagrelor 
Median [IQR], 
Mean±SD, n [n%] 
Prasugrel 
Median [IQR],  
Mean±SD, n [n%] 
p-value 
 
PRU Baseline 162.8±83.3 171.8±87.0 0.61 
 1 month 96.1±66.4 82.6±50.1 0.26 
Inhibition [%] Baseline 3 [0-52] 0 [0-39] 0.25 
 1 month 59 [30-83] 63 [46-78] 0.75 
LPR (<85) Baseline 11 [55.0%] 9 [45.0%] 0.54 
 1 month 22 [45.8%] 26 [54.2%] 0.41 
HPR (>235) Baseline 9 [19.6%] 12 [25.0%] 0.53 
 1 month 1 [2.2%] 0 [0%] 1.00 
P2Y12 platelet inhibition was determined during the index-procedure [baseline] and one month follow-up. 
HPR: high on platelet reactivity, LPR: low on platelet reactivity, PRU: platelet reactivity unit, SD: 
standard deviation. 
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Figure Legends  
 
Figure 1. Enrollment Flow Diagram 
Patients were enrolled between May 2015 and October 2017. 51 patients in the ticagrelor group 
and 48 patients in the prasugrel group were analyzed for the primary endpoint. 
 
Figure 2. Microcirculatory resistance in patients randomized to ticagrelor or prasugrel 
No significant difference in the index of microcirculatory resistance between patients 
randomized to ticagrelor or prasugrel during the index-procedure (baseline) and one month 
follow-up. Median values are denoted and the cross marks the mean value. The whiskers 
represent the minimal to maximal values with in between the median. 
 
Figure 3. Adenosine plasma concentration 
No significant difference in adenosine levels between patients randomized to ticagrelor or 
prasugrel during the index-procedure (baseline) and one month follow-up. The whiskers indicate 
the 10-90 percentile range, with in between the median. The mean is marked by the cross. 
 
Figure 4. Ticagrelor levels 
Ticagrelor levels are represented in a scatter plot for patients randomized to ticagrelor and 
prasugrel with specification of those patients who switched to a different therapy during follow-
up. The cross denotes the median and interquartile range. There were no significant differences 
in the ticagrelor level during the index-procedure at baseline. At one month follow-up 
significantly higher levels of ticagrelor were observed in the ticagrelor group 
 
D
ow
nloaded from
 http://ahajournals.org by on January 17, 2019
D
ow
nloaded from
 http://ahajournals.org by on January 17, 2019
D
ow
nloaded from
 http://ahajournals.org by on January 17, 2019
D
ow
nloaded from
 http://ahajournals.org by on January 17, 2019
D
ow
nloaded from
 http://ahajournals.org by on January 17, 2019
